These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 33796113)

  • 21. Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study.
    Schindler P; Bellmann-Strobl J; Kuhle J; Wildemann B; Jarius S; Paul F; Ruprecht K
    Mult Scler Relat Disord; 2024 Aug; 88():105729. PubMed ID: 38901371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
    Fujihara K; Cook LJ
    Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
    Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
    Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
    Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
    Jurynczyk M; Probert F; Yeo T; Tackley G; Claridge TDW; Cavey A; Woodhall MR; Arora S; Winkler T; Schiffer E; Vincent A; DeLuca G; Sibson NR; Isabel Leite M; Waters P; Anthony DC; Palace J
    Acta Neuropathol Commun; 2017 Dec; 5(1):95. PubMed ID: 29208041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Cortese R; Prados Carrasco F; Tur C; Bianchi A; Brownlee W; De Angelis F; De La Paz I; Grussu F; Haider L; Jacob A; Kanber B; Magnollay L; Nicholas RS; Trip A; Yiannakas M; Toosy AT; Hacohen Y; Barkhof F; Ciccarelli O
    Neurology; 2023 Jan; 100(3):e308-e323. PubMed ID: 36192175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.
    Messina S; Mariano R; Geraldes R; Kim SH; Satukijcha C; Vecchio D; Chua YY; Taylor J; George N; Cavey A; Diaz AR; Reeve S; Everett R; De Luca G; Leite MI; Kim HJ; Palace J
    Mult Scler Relat Disord; 2021 Apr; 49():102773. PubMed ID: 33540279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
    Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2024; 15():1454474. PubMed ID: 39224593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Akaishi T; Misu T; Fujihara K; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Nakashima I
    J Neurol; 2022 Jun; 269(6):3136-3146. PubMed ID: 34820735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
    Ringelstein M; Ayzenberg I; Lindenblatt G; Fischer K; Gahlen A; Novi G; Hayward-Könnecke H; Schippling S; Rommer PS; Kornek B; Zrzavy T; Biotti D; Ciron J; Audoin B; Berthele A; Giglhuber K; Zephir H; Kümpfel T; Berger R; Röther J; Häußler V; Stellmann JP; Whittam D; Jacob A; Kraemer M; Gueguen A; Deschamps R; Bayas A; Hümmert MW; Trebst C; Haarmann A; Jarius S; Wildemann B; Grothe M; Siebert N; Ruprecht K; Paul F; Collongues N; Marignier R; Levy M; Karenfort M; Deppe M; Albrecht P; Hellwig K; Gold R; Hartung HP; Meuth SG; Kleiter I; Aktas O;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34785575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Aktas O; Smith MA; Rees WA; Bennett JL; She D; Katz E; Cree BAC;
    Ann Neurol; 2021 May; 89(5):895-910. PubMed ID: 33724534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
    J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
    J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    Duan Y; Zhuo Z; Li H; Tian DC; Li Y; Yang L; Gao C; Zhang T; Zhang X; Shi FD; Barkhof F; Liu Y
    J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):709-716. PubMed ID: 33687975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
    Goldman-Yassen A; Lee A; Gombolay G
    Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
    Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
    Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage.
    Hyun JW; Kim Y; Kim KH; Kim SH; Olesen MN; Asgari N; Siritho S; Paul F; Kim HJ
    J Neuroinflammation; 2022 Apr; 19(1):86. PubMed ID: 35413922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
    Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.